Three months after cutting its Revenue growth target and seeing its shares slide 6% in a day, Smith & Nephew faces a fresh test with its third-quarter trading statement on Wednesday.

The reset that still frames the story

When Smith & Nephew (LSE:SN.) last spoke to the market in early August, the message was not the one investors had hoped to hear. The FTSE 100 medical technology group cut its guidance for full-year adjusted revenue growth to about 4%, down from 6%. The shares fell 6% on the day.

That reset is the lens through which Wednesday's third-quarter trading statement will be read. The update, due on Wednesday 4 November, is the company's first chance since August to show whether the lowered target is holding, slipping or looking too cautious. No figures have been published yet, so the focus is on the yardsticks the company set for itself.

The numbers from August give investors a clear checklist. Second-quarter adjusted revenue rose 1.6% to $1.59bn, short of the $1.63bn analysts had forecast. That shortfall works out at roughly $40m, or about 2.5% below expectations. Orthopaedics revenue came in at $614m, roughly flat, against forecasts of $646m. Wound care slipped 1% to $460m.

If one line in Wednesday's statement draws the sharpest scrutiny, it is likely to be orthopaedics. The division missed expectations by around $32m in the second quarter, and chief executive Deepak Nath did not shy away from the problem at the time. "Orthopaedics is not where we want it to be," he said.

That frank admission set the tone. Investors will now want to know whether the Business has stabilised, whether it has started to recover, or whether the weakness that weighed on the second quarter has persisted into the third. Any change in tone from management will be closely parsed, particularly given how sharply the shares reacted in August.

Wound care deserves attention too. A 1% decline is modest, but in a quarter when the group missed its revenue forecast, every division's contribution mattered. A return to growth there would help the overall picture; further softness would add to the pressure.

Profit held up better than sales

August was not all bad news. Smith & Nephew's first-half trading profit rose 8.1% to $566m, and the trading profit Margin improved to 18.3% from 17.7%. Crucially, the company kept its expectation of trading profit growth of about 8% for the full year, even as it lowered the revenue target.

That combination, slower sales growth but steady profit growth, points to a business leaning on efficiency and margin improvement while top-line momentum lags. Wednesday's statement will help show whether that balance is sustainable. A trading update typically focuses on revenue rather than detailed profit figures, so investors may look for any comment on whether the 8% profit growth ambition remains intact.

Illustration: To see what a two-point cut in growth guidance means in money terms, take a hypothetical company with $6bn of revenue last year. At 6% growth, revenue would rise to $6.36bn ($6bn × 1.06). At 4% growth, it would reach $6.24bn ($6bn × 1.04). The gap between the two is $120m of revenue. These numbers are invented to show the scale of a guidance change and are not Smith & Nephew's figures.

A different market from August

Smith & Nephew returns to the stage in a market that has moved on considerably since the summer. The FTSE 100 closed on Monday 2 November at 10,761.33, up 0.3% and on a four-session winning streak. October brought the index its first monthly gain in three months. The Blue-Chip benchmark now sits about 2.1% below its 2026 high of 10,989.45.

Healthcare shares have been volatile. The FTSE 350 pharmaceuticals sector fell 0.7% on Monday, but that followed a rise of more than 5% on Friday, its biggest daily gain in about 13 months. Smith & Nephew is a medical device maker rather than a drug company, but swings in sentiment towards healthcare can ripple across the wider sector.

Monday's main story was oil. Brent Crude dropped to around $105 a barrel from $117.61 on Friday, on reports that the US and Iran were weighing renewed indirect talks. That slide hit energy stocks hard, with BP (LSE:BP.) down 4.37%, but lifted consumer, travel and construction names.

The dollar is worth a thought as well. Smith & Nephew reports in US dollars, and sterling closed at $1.3417 on Monday. Currency movements can affect how dollar-reported figures translate for London-based investors. The US midterm elections on Tuesday and US October payrolls on Friday could both move the dollar this week.

Smith & Nephew will be one of seven FTSE 100 companies updating the market on Wednesday. Marks & Spencer (LSE:MKS) publishes half-year results, while Barratt Redrow (LSE:BTRW), Coca-Cola HBC (LSE:CCH), Lion Finance Group (LSE:BGEO), Prudential (LSE:PRU) and Weir Group (LSE:WEIR) also report. Eurozone Inflation figures, expected to rise to 3.9%, land the same day.

The following morning, the Bank of England announces its rate decision. Markets are pricing a roughly 95% chance of a quarter-point rise from 3.75% to 4%, which would be the first increase in more than three years.

Key dates to watch

  • Tuesday 3 November: US midterm elections
  • Wednesday 4 November: Smith & Nephew Q3 trading statement
  • Wednesday 4 November: Eurozone inflation, expected to rise to 3.9%
  • Thursday 5 November: Bank of England rate decision
  • Friday 6 November: US October payrolls

The bottom line

Smith & Nephew's third-quarter trading statement is its first report card since August's growth reset, when revenue guidance was cut to about 4% and the shares fell 6%. Orthopaedics, which Deepak Nath admitted was not where the company wanted it to be, is likely to be the focal point, with wound care and any comment on the 8% trading profit growth target close behind. Investors will be watching whether the lowered bar is being cleared, and whether management's tone has changed since the summer.